Italy updates product information for three buprenorphine medicines
Italy's medicines agency AIFA has approved changes to the marketing permissions for the buprenorphine medicines Busette, Busetalt and Buprenorfina Sandoz, held by Sandoz S.p.A. The decision, AAM/PPA 606/2026, is dated 30 October 2026 and was published on 7 November 2026. The changes update the technical product information and patient leaflets, and the process is a joint EU review, meaning one member state reviewed the change for all countries.
This summary was generated by AI; the official source prevails.
What does it mean?
These three pain-relief and addiction-treatment medicines now have updated safety and usage information. Pharmacies must hand out the revised leaflet to patients from thirty days after publication, while older stock can still be sold until it expires.
Who is affected?
Patients who use Busette, Busetalt or Buprenorfina Sandoz, and the pharmacists who dispense them.